<DOC>
	<DOCNO>NCT01568073</DOCNO>
	<brief_summary>This study aim demonstrate efficacy safety BIA 9-1067 , compare entacapone placebo , administer exist treatment L-DOPA plus Dopa Decarboxylase Inhibitor ( DDCI ) , patient Parkinson 's Disease ( PD ) end-of-dose motor fluctuation .</brief_summary>
	<brief_title>Efficacy Safety BIA 9-1067 Idiopathic Parkinson 's Disease Patients With `` Wearing-off '' Phenomenon</brief_title>
	<detailed_description>Efficacy safety BIA 9-1067 idiopathic Parkinson 's disease patient `` wearing-off '' phenomenon treat levodopa plus dopa decarboxylase inhibitor ( DDCI ) : double-blind , randomise , placebo- active-controlled , parallel-group , multicentre clinical study .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Benserazide</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Dopa Decarboxylase</mesh_term>
	<mesh_term>Aromatic Amino Acid Decarboxylase Inhibitors</mesh_term>
	<criteria>V1 ( Screening , 14 day V2 ) Able comprehend willing sign inform consent form . Male female subject 30 83 year old , inclusive . Diagnosed idiopathic PD accord UK Parkinson 's Disease Society Brain Bank Clinical Diagnostic Criteria least 3 year . Disease severity Stages IIII ( modify Hoehn &amp; Yahr stag ) ON . Treated LDOPA/DDCI least 1 year clear clinical improvement per investigator 's judgment . Treated 3 8 daily dos LDOPA/DDCI , include slowrelease formulation . On stable regimen LDOPA/DDCI antiPD drug least 4 week screen . Signs `` wearingoff '' phenomenon ( endofdose deterioration ) minimum 4 week screen , average total daily OFF time awake least 1.5 hour , exclude early morning prefirst dose OFF , despite optimal antiPD therapy ( base investigator 's judgment ) . Able keep reliable diary motor fluctuation ( alone family/caregiver assistance ) . Amenorrheic least 1 year surgically sterile least 6 month screen . Females childbearing potential must use effective nonhormonal contraceptive method . V2 ( Randomisation , Day 0 ) Have filledin selfrating diary chart accordance diary chart instruction ≤ 3 error per day . At least 1.5 OFF hour per day , exclude early morning prefirst dose OFF period ( i.e . time wakeup response first L DOPA/DDCI dosage ) , record selfrating diary least 2 3 day precede V2 . Results screen laboratory test consider acceptable investigator ( i.e . clinically relevant wellbeing subject purpose study ) . V1 ( Screening , 14 day V2 ) Nonidiopathic PD ( atypical parkinsonism , secondary [ acquire symptomatic ] parkinsonism , Parkinsonplus syndrome ) . Dyskinesia disability score &gt; 3 Unified Parkinson 's Disease Rating Scale ( UPDRS ) Subsection IV A , item 33 . Severe and/or unpredictable OFF period . Treatment prohibited medication : tolcapone , neuroleptic , venlafaxine , monoamine oxidase inhibitor ( except selegiline 10 mg/day oral formulation 1.25 mg/day buccal absorption formulation rasagiline 1 mg/day ) , antiemetic antidopaminergic action ( except domperidone ) within month screening . Previous use entacapone . Treatment apomorphine , alphamethyldopa , reserpine within month screen likely need time study . Dosage change concomitant antiPD medication within 4 week screen . Previous plan ( entire study duration , include OL period ) deep brain stimulation . Previous stereotactic surgery ( e.g . pallidotomy , thalamotomy ) PD plan stereotactic surgery study period . Any IMP within 3 month ( within 5 halflives , whichever long ) screening . Any medical condition might place subject increase risk interfere assessment . Past ( within past year ) present history suicidal ideation suicide attempt . Current previous ( within past year ) diagnosis major depressive disorder , mania , bipolar disorder , psychosis , dysthymia , generalise anxiety disorder , alcohol substance abuse exclude caffeine nicotine , impulse control disorder ( e.g . pathological gambling ) , dementia eating disorder accord Diagnostic Statistical Manual Mental Disorders , 4th edition , text revision ( DSMIV ) American Psychiatric Association , 2000 criterion , determine investigator . A clinically relevant electrocardiogram ( ECG ) abnormality ( relevance assess cardiologist need ) . Current evidence unstable cardiovascular disease , include limited uncontrolled hypertension , myocardial infarction important systolic diastolic dysfunction , unstable angina , congestive heart failure ( New York Heart Association class ≥ III ) , significant cardiac arrhythmia ( Mobitz II 2nd 3rd degree AV block arrhythmia cause haemodynamic repercussion symptomatic bradycardia syncope ) . Prior renal transplant current renal dialysis . Pheochromocytoma , paraganglioma , catecholamine secretive neoplasm . Known hypersensitivity ingredient IMPs use . History neuroleptic malignant syndrome ( NMS ) NMSlike syndrome , nontraumatic rhabdomyolysis . History current cancer disease , investigator 's opinion would exclude subject study ( e.g . melanoma , prostate cancer ) . Unstable active narrowangle unstable wideangle glaucoma . History current evidence relevant disease context study , i.e . respect safety subject relate study condition , e.g . may influence absorption metabolism ( relevant liver disease ) IMP . Pregnant breastfeeding . V2 ( Randomisation , Day 0 ) Any abnormality liver enzyme ( alanine aminotransferase and/or aspartate aminotransferase ) &gt; 2 time upper limit normal range , screen laboratory test result . Plasma sodium &lt; 130 mmol/L , white blood cell count &lt; 3000 cells/mm3 , relevant clinical laboratory abnormality screen laboratory test result , investigator 's opinion , may compromise subject 's safety . Inadequate compliance concomitant LDOPA/DDCI antiPD drug Screening period .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>83 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Parkinson</keyword>
	<keyword>PD</keyword>
	<keyword>Wearing-off</keyword>
	<keyword>Levodopa/DDCI</keyword>
</DOC>